Proof-of-concept Study Evaluating the Safety and Efficacy of EBP921 in Delta Hepatitis (HDV)

Summary

The purpose of this study is to assess the optimal dose of EBP921 by comparing the efficacy and safety of 2 dose regimens in patients with chronic HDV.

Timeline

Start

2011-01

Primary completion

2013-04

Completion

2013-04

Outcome

Outcome not reported

Stopped (Enrollment): “the enrollment was slow and never completed.”

Drugs

Indications